New drug targets rare bile duct cancer in 235-Patient trial
NCT ID NCT04353375
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called HMPL-453 in people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer, that has a specific genetic change (FGFR2 fusion). The trial aims to see how well the drug shrinks tumors. About 235 adults will take the drug orally in cycles. It is an open-label, single-arm study, meaning everyone gets the drug and no placebo is used.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HMPL-453 tartrate (a targeted cancer drug)
What this could lead to
If successful, this could provide a new treatment option for people with a rare bile duct cancer that has specific genetic changes.
What could go wrong
This is an early-to-mid stage trial with no control group, so results may not confirm benefit. Side effects from the drug are possible and long-term safety is unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••